These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30305548)

  • 1. [Immunotherapy using T cells for treating viral infections].
    Takahashi S
    Rinsho Ketsueki; 2018; 59(10):2373-2379. PubMed ID: 30305548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
    Sutrave G; Blyth E; Gottlieb DJ
    Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
    Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
    J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
    Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation.
    Ottaviano G; Chiesa R; Feuchtinger T; Vickers MA; Dickinson A; Gennery AR; Veys P; Todryk S
    Cells; 2019 Jan; 8(1):. PubMed ID: 30646564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation.
    Kállay K; Kassa C; Réti M; Karászi É; Sinkó J; Goda V; Stréhn A; Csordás K; Horváth O; Szederjesi A; Tasnády S; Hardi A; Kriván G
    J Immunother; 2018 Apr; 41(3):158-163. PubMed ID: 29239916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunotherapy for viral infection after HSC transplantation.
    Moss P; Rickinson A
    Nat Rev Immunol; 2005 Jan; 5(1):9-20. PubMed ID: 15630425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral adoptive immunotherapy using antigen-specific T cells in allogeneic hematopoietic stem cell transplant recipients.
    Němečková Š; Roubalová K
    Epidemiol Mikrobiol Imunol; 2019; 68(3):144-148. PubMed ID: 31914780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with virus-specific T cells.
    Fuji S; Kapp M; Grigoleit GU; Einsele H
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):413-9. PubMed ID: 21925094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
    Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
    J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.
    O'Reilly RJ; Doubrovina E; Trivedi D; Hasan A; Kollen W; Koehne G
    Immunol Res; 2007; 38(1-3):237-50. PubMed ID: 17917029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
    Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
    Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
    Gerdemann U; Vera JF; Rooney CM; Leen AM
    J Vis Exp; 2011 May; (51):. PubMed ID: 21654628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
    Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
    Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.